Rhumbline Advisers Increases Stock Position in Xencor, Inc. (NASDAQ:XNCR)

Rhumbline Advisers increased its holdings in Xencor, Inc. (NASDAQ:XNCR) by 2.8% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 154,573 shares of the biopharmaceutical company’s stock after buying an additional 4,265 shares during the period. Rhumbline Advisers owned 0.25% of Xencor worth $2,926,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Victory Capital Management Inc. grew its position in Xencor by 16.4% during the fourth quarter. Victory Capital Management Inc. now owns 24,637 shares of the biopharmaceutical company’s stock worth $523,000 after buying an additional 3,477 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of Xencor by 6.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 520,698 shares of the biopharmaceutical company’s stock worth $11,054,000 after purchasing an additional 32,251 shares in the last quarter. BNP Paribas Financial Markets increased its position in shares of Xencor by 105.8% in the fourth quarter. BNP Paribas Financial Markets now owns 82,488 shares of the biopharmaceutical company’s stock worth $1,751,000 after purchasing an additional 42,403 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Xencor by 23.0% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 12,725 shares of the biopharmaceutical company’s stock valued at $278,000 after purchasing an additional 2,378 shares in the last quarter. Finally, Quadrant Capital Group LLC lifted its position in Xencor by 475.2% during the fourth quarter. Quadrant Capital Group LLC now owns 4,757 shares of the biopharmaceutical company’s stock valued at $101,000 after purchasing an additional 3,930 shares during the last quarter.

Analyst Ratings Changes

XNCR has been the topic of several research reports. Raymond James lowered their price objective on shares of Xencor from $58.00 to $40.00 and set a “strong-buy” rating on the stock in a research report on Friday, June 14th. Royal Bank of Canada restated an “outperform” rating and set a $31.00 price target on shares of Xencor in a research report on Tuesday, August 6th. JPMorgan Chase & Co. cut their price objective on Xencor from $30.00 to $27.00 and set an “overweight” rating for the company in a report on Wednesday, July 31st. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Xencor in a report on Monday, September 9th. Finally, BMO Capital Markets reaffirmed an “outperform” rating and issued a $32.00 target price on shares of Xencor in a research note on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $34.44.

Insider Transactions at Xencor

In related news, VP John R. Desjarlais sold 36,329 shares of Xencor stock in a transaction dated Tuesday, July 9th. The shares were sold at an average price of $18.32, for a total transaction of $665,547.28. Following the completion of the sale, the vice president now owns 192,319 shares in the company, valued at approximately $3,523,284.08. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 5.23% of the company’s stock.

Xencor Trading Down 0.9 %

Shares of Xencor stock opened at $20.85 on Thursday. The company has a quick ratio of 6.92, a current ratio of 6.92 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.63 billion, a price-to-earnings ratio of -9.52 and a beta of 0.66. Xencor, Inc. has a twelve month low of $15.31 and a twelve month high of $26.84. The business has a 50-day moving average price of $18.53 and a 200-day moving average price of $20.47.

Xencor (NASDAQ:XNCR) last released its quarterly earnings results on Monday, August 5th. The biopharmaceutical company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.25). Xencor had a negative net margin of 132.74% and a negative return on equity of 28.23%. The firm had revenue of $16.96 million for the quarter, compared to analysts’ expectations of $21.13 million. During the same quarter in the prior year, the business earned ($0.37) EPS. The business’s quarterly revenue was down 62.7% compared to the same quarter last year. Equities research analysts anticipate that Xencor, Inc. will post -4.17 EPS for the current fiscal year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.